Adoption of sales force effectiveness remains suboptimal across the US medtech industry, which means that companies are missing out on significant annual revenue uplift. But things are changing, and it’s no longer an issue to be delegated: SFE has risen all the way to CEO level.
From a commercial standpoint, medtech has historically been dominated more by sales than by the marketing function. There has also been a strong clinical focus: the clinician stakeholder has traditionally been top of the priority list in all matters regarding the delivery of care – and by a long way.
But that has been changing over time, and the gap between the clinical stakeholder and the economic stakeholder has now...
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
As pharmaceutical companies seek to transform how drug discounts are delivered under the 340B program, a federal ruling reinforces HRSA's authority. The industry must now wait for critical guidance from the Trump administration that could reshape compliance strategies and financial outcomes.
The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
